Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Profit After Tax (2016 - 2025)

Enanta Pharmaceuticals' Profit After Tax history spans 14 years, with the latest figure at -$11.9 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 46.44% year-over-year to -$11.9 million; the TTM value through Dec 2025 reached -$71.5 million, up 31.82%, while the annual FY2025 figure was -$81.9 million, 29.43% up from the prior year.
  • Profit After Tax reached -$11.9 million in Q4 2025 per ENTA's latest filing, up from -$18.7 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$11.9 million in Q4 2025 to a low of -$39.1 million in Q2 2023.
  • Average Profit After Tax over 5 years is -$26.8 million, with a median of -$27.2 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: plummeted 267.11% in 2021, then skyrocketed 46.44% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then skyrocketed by 33.28% to -$22.3 million in 2024, then skyrocketed by 46.44% to -$11.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Profit After Tax are -$11.9 million (Q4 2025), -$18.7 million (Q3 2025), and -$18.3 million (Q2 2025).